about
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsMetastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy.Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.Metastatic Diffuse Intrinsic Pontine Glioma to the Peritoneal Cavity Via Ventriculoperitoneal Shunt: Case Report and Literature Review.EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating CellsTargeted therapy for BRAFV600E malignant astrocytoma.A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelAcquired resistance to BRAF inhibition in BRAFV600E mutant gliomasInhibiting 4EBP1 in glioblastoma.Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancersFeasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children.Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant gliomaActivating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation.High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.Pure germinomas of the central nervous system: treatment strategies and outcomes.Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.Suprasellar Germinoma Presenting with Slipped Capital Femoral Epiphysis: Case Report.Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy.Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives.Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experienceCell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant gliomaEvaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to GlioblastomaDelayed Fluorodeoxyglucose Positron Emission Tomography Imaging in the Differentiation of Tumor Recurrence and Radiation Necrosis in Pediatric Central Nervous System Tumors: Case Report and Review of the LiteratureThe genetic landscape of anaplastic pleomorphic xanthoastrocytomaMechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBMMolecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendationsDriving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness
P50
Q26744268-88FBE4FC-F4BA-4B76-BA2D-C19BD6B6BD6AQ33276416-EE916061-62BA-40F2-B53B-F18790E10903Q33276475-C617A223-D350-493C-9D85-2693E5D6EF57Q33945802-4FB3B0A2-CCA1-4BF7-9834-0F046CDC5133Q35190966-4033E3C3-5119-4575-BF55-FF4414ABF0EFQ35905205-D5162E47-0D9D-45D4-89F2-7AC4E90BDC45Q36355848-3EBC1ED1-E529-46BC-83B1-F0E2D4DCB6ECQ36421110-9262061F-E030-4247-AB4B-4DF6B5450DCBQ36800148-D15CF12A-CCB8-4A60-8AB3-3F354443F849Q37003323-E88E5C8D-2451-42FD-B779-2E21003BD297Q37689031-6C5142AF-DC95-4B4C-8370-3864A6079ED5Q37702320-DFD53FD6-9969-403D-B825-2E984955E731Q38659417-55E5A914-EF75-42DC-AC2B-71B2F32576CFQ38670250-5D7E9BE3-F8D2-4B4F-8567-19664866199EQ38712296-32071DB4-EE2A-419D-80C6-F44F7CB8A0A7Q39347810-2899E0FE-2A60-48B1-AF61-0FDB6C748E66Q39420456-5187C4D1-58A5-4ABC-B58A-E04FC58C3857Q41346638-5972BACC-DE11-458B-9210-ADBF3704E07EQ42713614-10864674-912D-49AA-BFF1-566EA1A87339Q44749323-F8F300AD-3918-470A-9C2F-BD09E705821EQ44955649-53868A90-CEB5-4F33-AB61-10CF76F0BB45Q46122173-4BF069C4-7265-4230-A5BC-D50B463E0575Q46180665-E07A83C6-0C16-49F4-8219-7C5029E574D7Q50051453-5A856AF3-71BB-4D61-82E3-70BE7F598103Q50315177-03B7DDBA-2A0E-4AB3-9946-B67241AA8E48Q51039784-4669E585-2AFE-4604-9595-8AAE34CE5B7EQ55380394-069FD69A-F398-4D9B-B4B1-CDE488B61ACFQ57158493-A34B0193-4F1A-4CF1-9DFA-16F095EC9F6BQ58609746-07A7A2A0-E1FE-4829-B1FA-3F7845DA5594Q60916387-10921288-F662-448E-9633-F723785D3972Q90232466-94825BE2-48B1-42F0-8964-EC8B170B22B0Q90557068-BF5B80A5-220E-40B5-8237-3C806FE6A314Q91592481-AC1509A6-479C-4748-8905-7B50AD0942FCQ91916410-B642B02C-6A0B-4C65-A2EE-EBE866E4C053Q92751125-AF55B3CA-7278-4A79-8EDE-F269354551A7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Theodore P Nicolaides
@ast
Theodore P Nicolaides
@en
Theodore P Nicolaides
@es
Theodore P Nicolaides
@nl
Theodore P Nicolaides
@sl
type
label
Theodore P Nicolaides
@ast
Theodore P Nicolaides
@en
Theodore P Nicolaides
@es
Theodore P Nicolaides
@nl
Theodore P Nicolaides
@sl
prefLabel
Theodore P Nicolaides
@ast
Theodore P Nicolaides
@en
Theodore P Nicolaides
@es
Theodore P Nicolaides
@nl
Theodore P Nicolaides
@sl
P106
P31
P496
0000-0002-0637-1086